Mirna Therapeutics has appointed Clay Siegall as an outside director on its board.
Siegall is the co-founder, president, and CEO of Seattle Genetics. He previously held various positions with Bristol-Myers Squibb and the National Cancer Institute.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.
Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.
Olympic athletes this summer will also undergo gene doping testing, according to Wired.
A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.